DARA BioSciences Sponsors Educational Programming on The Balancing Act® in Support of Breast Cancer Awareness Month

  DARA BioSciences Sponsors Educational Programming on The Balancing Act® in
  Support of Breast Cancer Awareness Month

  Nancy Peacock, MD, of Tennessee Oncology, and Breast Cancer Survivor Julie
 Megee Discuss Supportive Care Options, Tamoxifen/Soltamox Therapy Adherence,
                              Patient Education

Balancing Act Breast Cancer Segment Airs on Lifetime Television on Oct. 14 and

Business Wire

RALEIGH, N.C. -- October 4, 2013

DARA BioSciences, Inc. (NASDAQ: DARA), an oncology supportive care
pharmaceutical company dedicated to providing health care professionals a
synergistic portfolio of medicines to help cancer patients adhere to their
therapy and manage side effects arising from their cancer treatment, is
sponsoring a breast cancer patient education segment on The Balancing Act^® ^ 
airing on Lifetime Television. The segment, which airs Oct. 14 and 21 at 7
a.m. EDT during Breast Cancer Awareness Month, features Nancy Peacock, MD,
Tennessee Oncology medical oncologist and breast cancer specialist at St.
Thomas Midtown Hospital in Nashville, Tenn., and breast cancer survivor Julie
Megee of Wrentham, Mass.

Nancy Peacock, MD, and breast cancer survivor, Julie Megee from Wrentham,
Mass., join The Balancing ...

Nancy Peacock, MD, and breast cancer survivor, Julie Megee from Wrentham,
Mass., join The Balancing Act(R) host Danielle Knox in studio and discuss
important oncology supportive care issues (Photo: Business Wire)

Dr. Peacock and Ms. Megee join The Balancing Act^® host Danielle Knox in
studio and discuss important oncology supportive care issues, including
patient compliance to tamoxifen, and how Soltamox^® (tamoxifen citrate) oral
solution may help benefit compliance. The segment also touches on side effects
of cancer treatment, including skin burns and oral mucositis caused by
radiation treatment and chemotherapy. DARA markets Gelclair^®, an oral rinse
gel for relief of oral mucositis pain, and Bionect^®, a topical treatment for
skin irritation and burns, in the US oncology/radiology markets. Dr. Peacock
and Julie also discuss the important role of patient educational resources
such as Breastcancer.org.

“We are pleased to partner with The Balancing Act^® to produce this
educational segment about breast cancer treatment and support, and appreciate
The Balancing Act’s commitment to breast cancer education and programming
during Breast Cancer Awareness Month,” said David J. Drutz, MD, DARA's chief
executive officer and chief medical officer. “We are grateful to Dr. Peacock
and Ms. Megee for sharing their experiences on national television, so that
others may learn from their insights and knowledge.”

One issue that ties Dr. Peacock and Ms. Megee together is tamoxifen therapy.
According to recently published National Comprehensive Cancer Network (NCCN)
Guidelines (Version 3.2013), tamoxifen is the most firmly established adjuvant
endocrine therapy for both premenopausal and postmenopausal women with
estrogen receptor-positive breast cancer. Tamoxifen is usually administered as
20mg daily for five years. The American Society of Clinical Oncology (ASCO)
Clinical Practice Guidelines published on July 8, 2013, recommends that in
women at increased risk of breast cancer age 35 or older, tamoxifen
prophylaxis (20mg per day for five years) should be discussed as an option to
reduce the risk of estrogen receptor (ER) positive breast cancer. Soltamox^®
(tamoxifen citrate) oral solution is bioequivalent to tamoxifen and is
prescribed for the same indications. Please see Soltamox Important Safety
Information and the Black Box Warning at the end of this press release. For
additional information and a copy of the complete Prescribing Information
visit www.soltamox.com.

Megee, a 41-year-old mother of two and owner of Perceptions Hair Studio in
Norton, Mass., asked her physician about the option of using Soltamox^®
instead of tamoxifen tablets because of her long-standing aversion to pills.
Dr. Peacock recommends physicians discuss the importance of adherence to
tamoxifen/Soltamox^® therapy in detail because many patients do not realize
its significance in preventing the recurrence of breast cancer. Studies show
between 30 and 70 percent of patients who are prescribed tamoxifen as adjuvant
therapy fail to complete their prescribed course of treatment which can
increase the risk of breast cancer recurrence.

Education and support from family, friends and other women who have battled
breast cancer play key roles in patients’ lives, said both Dr. Peacock and Ms.
Megee. Both discuss the value and importance of online educational resources
and communities like Breastcancer.org.

“We are thrilled that Dr. Peacock and Ms. Megee turn to online resources like
Breastcancer.org as we are dedicated to providing the most reliable, complete,
and up-to-date information about breast cancer to help women and their loved
ones make informed decisions for their lives,” Rita Lusen, vice president of
corporate partnerships and marketing of Breastcancer.org. “Thank you and
congratulations to DARA and The Balancing Act^® on producing this timely
educational segment about breast cancer and supportive care.”

About DARA BioSciences

DARA BioSciences Inc. is an oncology supportive care pharmaceutical company
dedicated to providing healthcare professionals a synergistic portfolio of
medicines to help cancer patients adhere to their therapy and manage side
effects arising from their cancer treatment.

DARA holds exclusive U.S. marketing rights to Soltamox^® (tamoxifen citrate)
oral solution, the only liquid form of tamoxifen, used for the treatment and
prevention of breast cancer. Soltamox^® offers a choice to patients who prefer
or need a liquid form of tamoxifen. Gelclair^® is an alcohol-free bioadherent
oral rinse gel for rapid and effective relief of pain associated with oral
mucositis caused by chemotherapy and radiation treatment. DARA licensed the
U.S. rights to Soltamox^® from UK-based Rosemont Pharmaceuticals, Ltd., and
Gelclair^® from the Helsinn Group in Switzerland. Under an agreement with
Innocutis, DARA also markets Bionect (hyaluronic acid sodium salt, 0.2%), a
topical treatment for skin irritation and burns associated with radiation
therapy, in US oncology/radiology markets.

DARA is focused on expanding its portfolio of oncology supportive care
products in the US, via in-licensing and/or partnering of complementary
late-stage and approved products. In addition, the company wishes to identify
a strategic partner for the clinical development of KRN5500, currently in
Phase 2 for the treatment of chronic, treatment refractory, chemotherapy
induced peripheral neuropathy (CCIPN). The FDA has designated KRN5500 as a
Fast Track Drug, and DARA is seeking orphan status for the treatment of CCIPN.

For additional information about Gelclair and a copy of the full Prescribing
Information please visit www.gelclair.com. For additional information about
Bionect and a copy of the full Prescribing Information please visit

About Breastcancer.org

Breastcancer.org is the #1 online resource for breast health and breast cancer
information and support, with more than 6,000 pages of expert-reviewed
information and a robust, dynamic peer support community. A nonprofit
organization, Breastcancer.org receives more than 12 million visits each year.

About The Balancing Act^® on Lifetime Television

Now in its 6th year, The Balancing Act^® continues to empower women in all
aspects of their lives. The mission at The Balancing Act^® is simple -- the
show strives to help today’s modern woman balance it all by bringing them
exceptional solutions to everyday problems. Entertaining, educational and
trusted by women, viewers can watch America’s premier morning show The
Balancing Act^® weekday mornings on Lifetime television at 7 am (ET/PT).

For additional information or to view a segment visit www.thebalancingact.com


Tamoxifen citrate is contraindicated in patients with known hypersensitivity
and also in women who require concomitant coumarin-type anticoagulant therapy
or in women with a history of deep vein thrombosis or pulmonary embolus. As
with other additive hormonal therapy (estrogens and androgens), hypercalcemia
has been reported in some breast cancer patients with bone metastases within a
few weeks of starting treatment with tamoxifen. If hypercalcemia does occur,
appropriate measures should be taken and, if severe, tamoxifen should be
discontinued. There is evidence of an increased incidence of thromboembolic
events, including deep vein thrombosis and pulmonary embolism, during
tamoxifen therapy. When tamoxifen is coadministered with chemotherapy, there
may be a further increase in the incidence of thromboembolic effects. Adverse
reactions to tamoxifen are relatively mild and rarely severe enough to require
discontinuation of treatment in breast cancer patients.


In Women with Ductal Carcinoma in Situ (DCIS) and Women at High Risk for
Breast Cancer Serious and life-threatening events were associated with
tamoxifen in the risk reduction setting (women at high risk for cancer and
women with DCIS) include uterine malignancies, stroke and pulmonary embolism.
(see CLINICAL PHARMACOLOGY, Clinical Studies, Reduction in Breast Cancer
Incidence In High Risk Women). Health care providers should discuss the
potential benefits versus the potential risks of these serious events with
women at high risk of breast cancer and women with DCIS considering tamoxifen
to reduce their risk of developing breast cancer. The benefits of tamoxifen
outweigh its risks in women already diagnosed with breast cancer.

You are encouraged to report negative side effects of prescription drugs to
the FDA. Visit www.fda.gov/medwatch, or call 1-855-273 0468

Safe Harbor Statement

All statements in this news release that are not historical are
forward-looking statements within the meaning of the Securities Exchange Act
of 1934, as amended. Such forward-looking statements are subject to factors
that could cause actual results to differ materially for DARA from those
projected. Important factors that could cause actual results to differ
materially from the expectations described in these forward-looking statements
are set forth under the caption “Risk Factors” in DARA’s most recent Annual
Report on Form 10-K, filed with the SEC on March 28, 2013. Those factors
include risks and uncertainties relating to DARA's ability to timely
commercialize and generate revenues or profits from Bionect®, Soltamox®,
Gelclair® or other products given that DARA only recently hired its initial
sales force and DARA's lack of history as a revenue-generating company, FDA
and other regulatory risks relating to DARA's ability to market Bionect,
Soltamox, Gelclair or other products in the U.S. or elsewhere, DARA's ability
to develop and bring new products to market as anticipated, DARA's current
cash position and its need to raise additional capital in order to be able to
continue to fund its operations, the current regulatory environment in which
DARA develops and sells its products, the market acceptance of those products,
dependence on partners, successful performance under collaborative and other
commercial agreements, competition, the strength of DARA's intellectual
property and the intellectual property of others, the potential delisting of
DARA's common stock from the NASDAQ Capital Market, risks and uncertainties
relating to DARA's ability to successfully integrate Oncogenerix and other
risk factors identified in the documents DARA has filed, or will file, with
the Securities and Exchange Commission ("SEC"). Copies of DARA's filings with
the SEC may be obtained from the SEC Internet site at http://www.sec.gov. DARA
expressly disclaims any obligation or undertaking to release publicly any
updates or revisions to any forward-looking statements contained herein to
reflect any change in DARA's expectations with regard thereto or any change in
events, conditions, or circumstances on which any such statements are based.
DARA BioSciences and the DARA logo are trademarks of DARA BioSciences, Inc.

Keywords: Balancing Act, DARA BioSciences, tamoxifen, liquid tamoxifen,
Soltamox, ductal carcinoma in situ, node-positive breast cancer, Tennessee
Oncology, St. Thomas Midtown Hospital, breast cancer, estrogen receptor
positive, liquid formulation.

Photos/Multimedia Gallery Available:



Media Contacts:
LaVoie Group
David Connolly or Samantha Stenbeck, 617-374-8800
Corporate Contact:
DARA BioSciences
Jenene Thomas, 908-938-1475
Press spacebar to pause and continue. Press esc to stop.